Back to School: How biopharma can reboot drug development. Access exclusive analysis here
AEZ will restructure and seek to divest non-core assets to focus on endocrine therapy and oncology.
Sign in to your BioCentury account to access your content.
Get a two-week free trial subscription to BioCentury